- Home
- NAUT vs LXEO Comparison
NAUT vs LXEO Comparison
Compare NAUT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- LXEO
- Stock Information
- Founded
- NAUT 2016
- LXEO 2017
- Country
- NAUT United States
- LXEO United States
- Employees
- NAUT N/A
- LXEO N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- LXEO
- Sector
- NAUT Industrials
- LXEO
- Exchange
- NAUT Nasdaq
- LXEO Nasdaq
- Market Cap
- NAUT 91.5M
- LXEO 93.9M
- IPO Year
- NAUT N/A
- LXEO 2023
- Fundamental
- Price
- NAUT $0.77
- LXEO $4.49
- Analyst Decision
- NAUT Strong Sell
- LXEO Strong Buy
- Analyst Count
- NAUT 1
- LXEO 5
- Target Price
- NAUT $1.75
- LXEO $16.60
- AVG Volume (30 Days)
- NAUT 561.4K
- LXEO 520.2K
- Earning Date
- NAUT 07-29-2025
- LXEO 08-11-2025
- Dividend Yield
- NAUT N/A
- LXEO N/A
- EPS Growth
- NAUT N/A
- LXEO N/A
- EPS
- NAUT N/A
- LXEO N/A
- Revenue
- NAUT N/A
- LXEO N/A
- Revenue This Year
- NAUT N/A
- LXEO N/A
- Revenue Next Year
- NAUT N/A
- LXEO N/A
- P/E Ratio
- NAUT N/A
- LXEO N/A
- Revenue Growth
- NAUT N/A
- LXEO N/A
- 52 Week Low
- NAUT $0.66
- LXEO $1.45
- 52 Week High
- NAUT $3.09
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- NAUT 51.04
- LXEO 63.76
- Support Level
- NAUT $0.69
- LXEO $3.91
- Resistance Level
- NAUT $0.82
- LXEO $4.85
- Average True Range (ATR)
- NAUT 0.06
- LXEO 0.33
- MACD
- NAUT 0.00
- LXEO 0.02
- Stochastic Oscillator
- NAUT 50.00
- LXEO 78.69
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.